These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35179782)

  • 81. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 82. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 87. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis.
    Zhang Y; Liu JL; Wang J
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
    Whitworth PW; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Murray MK; Gittleman MA; Budway RJ; Rahman RL; Kelemen PR; Dooley WC; Rock DT; Cowan KH; Lesnikoski BA; Barone JL; Ashikari AY; Dupree BB; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
    JCO Precis Oncol; 2022 Apr; 6(1):e2100463. PubMed ID: 35476550
    [TBL] [Abstract][Full Text] [Related]  

  • 89. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Breast cancer and its therapeutic targets: A comprehensive review.
    Singh A; Mishra R; Mazumder A
    Chem Biol Drug Des; 2024 Jan; 103(1):e14384. PubMed ID: 37919259
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.
    Yuan H; Lu J; Xiao J; Upadhyay G; Umans R; Kallakury B; Yin Y; Fant ME; Kopelovich L; Glazer RI
    Cancer Res; 2013 Jul; 73(14):4349-61. PubMed ID: 23811944
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women.
    Park C; Yoon KA; Kim J; Park IH; Park SJ; Kim MK; Jang W; Cho SY; Park B; Kong SY; Lee ES
    Cancer Sci; 2019 May; 110(5):1760-1770. PubMed ID: 30811755
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.
    Asgari-Karchekani S; Aryannejad A; Mousavi SA; Shahsavarhaghighi S; Tavangar SM
    Med Oncol; 2022 Sep; 39(12):210. PubMed ID: 36175719
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.
    Houlahan KE; Khan A; Greenwald NF; Vivas CS; West RB; Angelo M; Curtis C
    Science; 2024 May; 384(6699):eadh8697. PubMed ID: 38815010
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The molecular profile of luminal B breast cancer.
    Creighton CJ
    Biologics; 2012; 6():289-97. PubMed ID: 22956860
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression.
    Cyrta J; Benoist C; Masliah-Planchon J; Vieira AF; Pierron G; Fuhrmann L; Richardot C; Caly M; Leclere R; Mariani O; Da Maia E; Larousserie F; Féron JG; Carton M; Renault V; Bidard FC; Vincent-Salomon A
    Mod Pathol; 2022 Nov; 35(11):1624-1635. PubMed ID: 35697931
    [TBL] [Abstract][Full Text] [Related]  

  • 98. NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence.
    Mendiburu-Eliçabe M; García-Sancha N; Corchado-Cobos R; Martínez-López A; Chang H; Mao JH; Blanco-Gómez A; García-Casas A; Castellanos-Martín A; Salvador N; Jiménez-Navas A; Pérez-Baena MJ; Sánchez-Martín MA; Abad-Hernández MDM; Del Carmen S; Claros-Ampuero J; Cruz-Hernández JJ; Rodríguez-Sánchez CA; García-Cenador MB; García-Criado FJ; Vicente RS; Castillo-Lluva S; Pérez-Losada J
    Res Sq; 2023 Oct; ():. PubMed ID: 37886490
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.
    Zahavi T; Salmon-Divon M; Salgado R; Elkin M; Hermano E; Rubinstein AM; Francis PA; Di Leo A; Viale G; de Azambuja E; Ameye L; Sotiriou C; Salmon A; Kravchenko-Balasha N; Sonnenblick A
    NPJ Breast Cancer; 2021 May; 7(1):67. PubMed ID: 34050190
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer.
    Bartl T; Grimm C; Mader RM; Zielinski C; Prager G; Unseld M; Herac-Kornauth M
    J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.